Reovirus safety study for proliferation and differentiation of human adipose-derived mesenchymal stem cells

被引:0
作者
Jeong-Soo Park
Manbok Kim
机构
[1] Dankook University College of Medicine,Department of Biochemistry
[2] Dankook University College of Medicine,Department of Medical Science
来源
Journal of Microbiology | 2017年 / 55卷
关键词
oncolytic virus; reovirus; safety; human adipose-derived mesenchymal stem cells;
D O I
暂无
中图分类号
学科分类号
摘要
Naturally occurring reoviruses are live replication-proficient viruses specifically infecting human cancer cells while sparing the normal counterparts. Stem cells can be highly susceptible to viral infection due to their innate high proliferation potential and other active signaling pathways of cells that might be involved in viral tropism. In the previous study, we showed that reoviruses could adversely affect murine embryonic stem cells’ integrity in vitro and in vivo. Oncolytic viruses, delivered systemically face many hurdles that also impede their localization and infection of, metastatic tumors, due to a variety of immune and physical barriers. To overcome such hurdles to systemic delivery, several studies supported the idea that certain types of cells, including mesenchymal stem cells, might play a role as cell carriers for oncolytic viruses. Thus, it would be interesting to examine whether human adult stem cells such as human adipose-derived mesenchymal stem cells could be saved by the reoviral challenge. In this study, we report that biological activities such as proliferation and multipotency of human adipose-derived stem cells are not affected by wild-type reovirus challenge as evidenced by survival, osteogenic and adipogenic differentiation potential assays following treatment with reoviruses. Therefore, unlike murine embryonic stem cells, our study strongly suggests that human adipose-derived adult stem cells could be spared in vivo during wild-type reoviral anti-cancer therapeutics in a clinical setting. Furthermore, the results support the possible clinical use of human adipose-derived stem cells as an effective cell carrier of oncolytic reovirus to maximize their tumor tropism and anti-tumor activity.
引用
收藏
页码:75 / 79
页数:4
相关论文
共 111 条
[1]  
Clements D.(2014)Reovirus in cancer therapy: an evidence-based review Oncolytic Virother. 3 69-82
[2]  
Helson E.(2011)Type I interferon signaling limits reoviral tropism within the brain and prevents lethal systemic infection J. Neurovirol. 17 314-326
[3]  
Gujar S.A.(2007)Mesenchymal stem cells in cancer tumor–associated fibroblasts and cell-based delivery vehicles Int. J. Hematol. 86 8-16
[4]  
Lee P.W.(1997)Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells J. Cell. Biochem. 64 295-312
[5]  
Dionne K.R.(2015)Naturally occurring reoviruses for human cancer therapy BMB Rep. 48 454-460
[6]  
Galvin J.M.(2007)Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells Oncogene 26 4124-4134
[7]  
Schittone S.A.(2011)Attenuated reovirus displays oncolysis with reduced host toxicity Br. J. Cancer 104 290-299
[8]  
Clarke P.(2010)The viral tropism of two distinct oncolytic viruses, reovirus, and myxoma virus, is modulated by cellular tumor suppressor gene status Oncogene 29 3990-3996
[9]  
Tyler K.L.(2004)Morbidity in immunosuppressed (SCID/ NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic Cancer Biol. Ther. 3 734-738
[10]  
Hall B.(2016)Replicating viruses for gynecologic cancer therapy Eur. J. Gynaecol. Oncol. 37 295-304